Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical

Primary objective: To compare the differences in absorption degree and speed of desloratadine tablets (specification: 5 mg) provided by Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical Co., Ltd. and desloratadine tablets (specification: 5 mg, trade name: Enlisi®) certified by N.V. Organon in healthy people under fasting and postprandial administration conditions. Secondary objective: To evaluate the safety of desloratadine tablets (specification: 5 mg) provided by Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical Co., Ltd. and desloratadine tablets (specification: 5 mg, trade name: Enlisi®) certified by N.V. Organon under fasting and postprandial conditions.

Main purpose: Using pharmacokinetic parameters as the primary endpoint evaluation indicators, the pharmacokinetic behavior of the test preparation calcitriol soft capsule (licensed by Zhejiang Huarun Sanjiu Zhongyi Pharmaceutical Co., Ltd.) and the reference preparation calcitriol capsule (licensed by Roche Pharma (Schweiz) AG, trade name: Rogaquan®) in healthy subjects after oral administration in the fasting/postprandial state was compared to evaluate the bioequivalence of the two preparations. Secondary purpose: Observe the safety of the test preparation calcitriol soft capsule and the reference preparation calcitriol capsule in healthy subjects.

Primary Objective: To observe the pharmacokinetic characteristics of the test formulation repaglinide tablets (1.0 mg; manufactured by Zhejiang CR Sanjiu Zhongyi Pharmaceutical Co., Ltd.) and the reference formulation repaglinide tablets (trade name: Novo Nordisk®; 1.0 mg; manufactured by Boehringer Ingelheim Pharma GmbH & Co. KG, Germany; licensee: Novo Nordisk A/S) after a single oral administration in healthy participants in a Chinese healthy trial, under fasting/postprandial conditions, and to evaluate the bioequivalence of the two formulations under fasting/postprandial conditions. Secondary Objective: To observe the safety of the test formulation repaglinide tablets and the reference formulation repaglinide tablets (Novo Nordisk®) in healthy participants in a Chinese healthy trial.